Answers are grounded in this paper and cite their sources.
The capsules of invasive bacteria shield underlying antigens, limit immune clearance and hinder vaccine noncapsular antigen discovery. To address this, we developed Liver-based Vaccine Antigen Capture (L-VAC), a functional platform integrating antibody-mediated screening with in vivo visualization of hepatic bacterial clearance in mice. Applying L-VAC to Streptococcus pneumoniae identified multiple capsule-permeable proteins that induce rapid hepatic clearance of blood-borne bacteria. Immunization with these proteins, especially in a multivalent formulation, conferred broad cross-serotype protection. Spatial analyses revealed that only the proteins localized at or near the capsular surface are targetable for vaccine-induced pathogen capture in the liver sinusoids. These findings establish L-VAC as a sensitive and reliable approach for identifying protective protein antigens capable of overcoming capsule barriers, offering a promising strategy to develop broadly protective vaccines against multidrug-resistant encapsulated pathogens.
No takes yet. Share an insight, caveat, or question.
Jin et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: